{"id":"W4300981046","doi":"10.1038/s41591-022-02070-0","title":"Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial","year":2022,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Genetic Neurodegenerative Diseases","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal; University of British Columbia","funders":"","keywords":"Blockade; Placebo; Antibody; Medicine; Huntington's disease; Randomized controlled trial; Internal medicine; Disease; Pharmacology; Oncology; Immunology; Pathology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00652983,0.002292986,0.003062962,0.002518019,0.001943051,0.003575075,0.003348523,0.007673336,0.04214735],"category_scores_gemma":[0.05443932,0.001223718,0.002743451,0.00177407,0.001763906,0.001445789,0.0008585565,0.01019973,0.01599781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004617087,"about_ca_system_score_gemma":0.005767266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01565016,"about_ca_topic_score_gemma":0.02373932,"domain_scores_codex":[0.9961104,0.000935812,0.0007535405,0.0004283014,0.001496208,0.0002758084],"domain_scores_gemma":[0.9746134,0.01130714,0.001601736,0.001262359,0.009994445,0.001220989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0002057461,0.000009049133,0.0000474757,0.0003268574,0.00005641616,0.0002577483,0.000009345676,0.00003802085,0.00004363504,0.0003637716,0.9938261,0.004815729],"study_design_scores_gemma":[0.001858266,0.0001306412,0.001379786,0.001583362,0.0006057795,0.0008784769,0.0000491692,0.0003893477,0.0005546802,0.001662274,0.990831,0.00007718379],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001372117,0.002678944,0.0003909135,0.04625677,0.9467134,0.00007361361,0.001114751,0.0001476013,0.002486848],"genre_scores_gemma":[0.01136868,0.01213682,0.004344987,0.2384832,0.512097,0.0007470554,0.002188996,0.001077674,0.2175556],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.04214735,"threshold_uncertainty_score":0.140997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01258796693486871,"score_gpt":0.3162602946205328,"score_spread":0.3036723276856642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}